Lipid compositions for nucleic acid delivery
View Patent ↗The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.
1. A lipid vesicle formulation comprising:
(a) a plurality of lipid vesicles, wherein each lipid vesicle comprises:
a cationic lipid;
an amphipathic lipid; and
a polyethyleneglycol (PEG)-lipid; and
(b) messenger RNA (mRNA), wherein at least 70% of the mRNA in the formulation is fully encapsulated in the lipid vesicles.
2. The lipid vesicle formulation of claim 1 , wherein the amphipathic lipid is a phospholipid.
3. The lipid vesicle formulation of claim 2 , wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, di stearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine.
4. The lipid vesicle formulation of claim 1 , wherein each lipid vesicle further comprises a sterol.
5. The lipid vesicle formulation of claim 4 , wherein the sterol is cholesterol.
6. The lipid vesicle formulation of claim 4 , wherein the sterol is cholesterol and the amphipathic lipid is a phospholipid.
7. The lipid vesicle formulation of claim 6 , wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, di stearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine.
8. The lipid vesicle formulation of claim 1 , wherein each lipid vesicle is a liposome.
9. The lipid vesicle formulation of claim 1 , wherein each lipid vesicle is a lipid-nucleic acid particle.
10. The lipid vesicle formulation of claim 1 , wherein each lipid vesicle is about 150 nm or less in diameter.
11. The lipid vesicle formulation of claim 1 , wherein the cationic lipid only carries a positive charge at below physiological pH.
12. The lipid vesicle formulation of claim 1 , wherein each lipid vesicle is about 100 nm or less in diameter.
13. The lipid vesicle formulation of claim 1 , wherein at least 80% of the mRNA in the formulation is fully encapsulated in the lipid vesicles.
14. The lipid vesicle formulation of claim 1 , wherein about 90% of the mRNA in the formulation is fully encapsulated in the lipid vesicles.